Olutasidenib for IDH1-Mutated AML After Initial Treatment
This study is looking at olutasidenib, a drug for acute myeloid leukemia (AML), after patients have already received intensive induction and/or consolidation therapy. It's for people aged 18 and older who have AML with a specific genetic change called an IDH1 mutation. Researchers want to see if olutasidenib is safe and well-tolerated (how well people can handle the treatment) when given twice daily for up to two years. They also hope it will help maintain remission and improve survival. The study plans to enroll up to 15 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It is a single-arm study, with up to 15 participants receiving olutasidenib.
- What's involved
- You would take olutasidenib by mouth twice daily for up to two years. You would also have regular monitoring for side effects, quality of life, and your disease status.
- Compensation
- Not stated in the trial record.
- Follow-up
- After stopping treatment, you will be followed for up to two years from the date you joined the study to track survival.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
NCT07130695
Olutasidenib Single Plus Combo Therapy in IDH1mut AML After Induction and Consolidation
Recruiting
PHASE1Ages 18+InterventionalTreatmentVirginia Commonwealth UniversityInvestigator-initiated
~15 participants
Updated 2026-02-06 on ClinicalTrials.gov
What's tested:Olutasidenib Investigational Agent Administration
At a glance
Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Assess the feasibility of olutasidenib after upfront acute myeloid leukemia (AML) therapy with intensive induction and/or consolidation in IDH1 mutant AML.
Measured over Up to 2 years
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesVirginia1
Study leadership
- Keri Maher, DO · PRINCIPAL_INVESTIGATOR · Virginia Commonwealth University
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Histologically or cytologically confirmed non-acute promyelocytic isocitrate dehydrogenase (1 IDH1) mutant acute myeloid leukemia (AML). IDH1 mutation may be identified by NGS or PCR based methods and identified at time of diagnosis or any other time point prior to enrollment.
Completed induction and/or consolidation intended as per treating physician to reach complete response (CR),complete response with partial hematologic recovery (CRh), or complete response with incomplete hematologic recovery (CRi), or morphologic leukemia free state (MLFS) at time of study enrollment Patients must be within 90 days of their last cycle of upfront therapy.
Age ≥18 years
Calculated creatinine clearance (by Cockroft-Gault) ≥30 mL/min
Total bilirubin ≤2 × upper limit of normal (ULN) Note: patients with Gilbert's syndrome may be included if total bilirubin is ≤3 × ULN and direct bilirubin is ≤2 × ULN
Serum aspartate aminotransferase/ alanine aminotransferase (AST/ALT) ≤3 × ULN
Eastern Cooperative Oncology Group (ECOG) 0, 1, or 2 or KPS \>50%
Able to take oral medications
Women of childbearing potential must consent to effective contraception during study treatment and at least 6 months following the last dose. Effective methods of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double- barrier methods. (ie, combination of male condom with either cap, diaphragm or sponge with spermicide)
Male participants who are sexually active with a woman of childbearing potential and who have not had vasectomies must be willing to use a barrier method of contraception and refrain from sperm donation from initial study drug until 90 days after last dose of study drug.
Exclusion
History of hypersensitivity or allergic reaction to olutasidenib or its components
Corrected Q-T interval (QTc) (Fredericia calculation) \> 450 ms (after corrective action is taken)
History of Torsades de Pointes
Any gastrointestinal condition thought by the treating investigator to impair oral absorption of medication
Stem cell transplant eligible and planned within 60 days of study start date in the opinion of the treating investigator
Uncontrolled intercurrent illness or infection (those with controlled human immunodeficiency virus (HIV), hepatitis, or other chronic infections are eligible)
Female participants who are pregnant or intend to donate eggs during the study or for 6 months after receiving their last dose of study drug
Nursing women, women of childbearing potential with positive pregnancy test, or women of childbearing potential who are not willing to maintain adequate contraception. (Appropriate method(s) of contraception include oral or injectable hormonal birth control, IUD, and double-barrier methods)
Male participants who intend to donate sperm during the course of this study or for 3 months after last dose
Participants receiving, or are expected to require during the study, any concomitant medications that may interfere with efficacy, metabolism, or safety of the investigational agent, including drugs known to cause QT prolongation. for which drug interactions with olutasidenib would be prohibitory
Concurrent chemotherapy for non-AML malignancy that is expected to interfere with the efficacy, metabolism, or safety of the agent under investigation
Received non-intensive upfront therapy including hypomethylating agents (HMA) /Venetoclax based
Currently receiving other targeted therapies or AML directed therapies, including but not limited to other IDH1 or IDH2 inhibitors, FMS-like tyrosine kinase 3 (FLT3) inhibitors, B-cell lymphoma 2 (BCL-2) inhibitors, menin inhibitors
Other investigational agents in another clinical trial within 4 weeks prior to enrollment
Systemic corticosteroids above physiologic replacement doses (10mg/day prednisone or equivalent), unless used to tread IDH differentiation syndrome or as part of a pre-specified protocol exception
Medical, psychological, or social condition that, in the opinion of the investigator, may increase the participant's risk or limit the participant's adherence with study requirements
What this trial measures
- Assess the feasibility of olutasidenib after upfront acute myeloid leukemia (AML) therapy with intensive induction and/or consolidation in IDH1 mutant AML.Up to 2 years
Feasibility defined as the number of participants with 75% protocol treatment compliance for a duration of at least 4 cycles (to include protocol defined dose delays), or until disease relapse or allogeneic hematopoietic stem cell transplant (alloHCT).
- Assess the tolerability of olutasidenib after upfront AML therapy with intensive induction and/or consolidation in IDH1 mutant AMLUp to 2 years
Incidence of grade ≥4 adverse events (AEs) attributable to study drug for duration of treatment on study